UNC Health Medication Formulary
Change Request Form Chemical/SDS Search UNC Health.org
QR Code Add Formweb to your mobile device
Android iOS
Click here to submit safety event reports via SAFE
UNC Health Medication Formulary
Change Request Form Chemical/SDS Search UNC Health.org
Search results for:

trastuzumab

trastuzumab
Drug Name Form Strength ARHS Blue Ridge Caldwell Chatham Johnston Lenoir Medical Center Nash Pardee Rex Rockingham Southeastern Wayne Youth Behavioral Health
Trastuzumab-anns (Kanjinti) POWDER FOR INJECTION, INTRAVENOUS 150 mg              
Trastuzumab-dkst (Ogivri) POWDER FOR INJECTION, INTRAVENOUS 150 mg                    
Trastuzumab-anns (Kanjinti) POWDER FOR INJECTION, INTRAVENOUS 420 mg              
Trastuzumab-dkst (Ogivri) POWDER FOR INJECTION, INTRAVENOUS 420 mg          

UNC Health

System Formulary Restriction:

Inpatient: no inpatient use allowed

Outpatient:

    • Ogivri: recommended first line product
    • Kanjinti: Restricted to those who meet the following criteria:
      • Continuation of therapy in patients who previously received Kanjinti
      • Initiation of therapy in patients with insurance restrictions that require Kanjinti or do not cover Ogivri

Med Center
     UNC Medical Center Formulary Restrictions

Rex
     Rex Hematology-Oncology Formulary Restrictions

Last updated: Jul. 23, 2026






This site is intended for the staff of UNC Health.
While others may view accessible pages, UNC Health makes no warranty, express or implied,
as to the use of this information outside of UNC Health.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved